Your vote is IMPORTANT!
Please vote your proxy online now or by phone by dialing 866-961-5580.
May 29, 2026
9:00 AM ET
This year our Annual Meeting will be held online.
You must register in order to join.
Forte Biosciences is a clinical-stage biopharmaceutical company whose lead product candidate is FB102. FB102 is a proprietary molecule with potentially broad autoimmune and autoimmune-related applications. In June 2025, we announced positive data from the FB102 celiac disease study. A Phase 2 celiac disease has been initiated with data expected in 2026. Additionally, a vitiligo trial has commenced enrollment with topline data expected in 1H26 and an alopecia areata trial is initiating in 2H25 with topline data expected in 2026.